Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced primarily in the L-cells of the distal small intestine and colon. Since its characterization in the 1980s, GLP-1 and its receptor agonists have become one of the most actively researched areas in metabolic and cardiometabolic medicine. This guide provides an overview of the GLP-1 system and the research landscape surrounding GLP-1 receptor agonist peptides.
What Is GLP-1?
GLP-1 is a 30-amino acid peptide derived from proglucagon through post-translational processing. It is secreted in response to nutrient ingestion — particularly carbohydrates and fats — and exerts its primary effects by binding to GLP-1 receptors (GLP-1R) expressed in the pancreas, brain, heart, gut, and other tissues.
The primary actions of endogenous GLP-1 include stimulation of glucose-dependent insulin secretion, inhibition of glucagon release, slowing of gastric emptying, reduction of appetite via central nervous system signaling, and promotion of β-cell proliferation and survival in preclinical models.
Free Tool
Peptide Reconstitution Calculator
Convert vial strength, water volume, and desired dose into precise syringe units. Works for BPC-157, TB-500, GHK-Cu, and all research peptides.
Try the Calculator →Why Native GLP-1 Isn’t Useful as a Therapeutic
Native GLP-1 has a plasma half-life of only 1–2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and renal clearance. This necessitated the development of modified analogs resistant to DPP-4 degradation, leading to the class of drugs known as GLP-1 receptor agonists (GLP-1 RAs).
GLP-1 Receptor Agonist Peptides in Research
Several generations of GLP-1 RAs have been developed, ranging from exenatide (derived from Gila monster saliva) to fully human analogs like liraglutide and semaglutide. More recent research has explored dual and triple receptor agonists that combine GLP-1R activity with GIP and glucagon receptor agonism.
| Compound | Receptor Targets | Half-Life | Research Focus |
|---|---|---|---|
| Semaglutide | GLP-1R | ~7 days | T2D, obesity, cardiovascular |
| Tirzepatide | GLP-1R + GIPR | ~5 days | T2D, weight loss |
| Retatrutide | GLP-1R + GIPR + GCGR | ~6 days | Obesity, NAFLD, metabolic disease |
| Liraglutide | GLP-1R | ~13 hours | T2D, obesity, NASH |
Semaglutide Research Overview
Semaglutide is a fatty-acid acylated GLP-1 analog with 94% sequence homology to native GLP-1. Its long half-life is achieved via albumin binding through its fatty acid chain, reducing renal clearance and DPP-4 susceptibility. Phase 3 trials (SUSTAIN, STEP programs) have demonstrated substantial glycemic control and weight reduction.
Tirzepatide: Dual GIP/GLP-1 Agonism
Tirzepatide represents the first approved dual GIP/GLP-1 receptor agonist. By combining agonism at both the GLP-1R and GIPR, tirzepatide demonstrated superior weight loss outcomes in SURMOUNT trials compared to semaglutide monotherapy in head-to-head analyses. The additive or synergistic effects of GIPR agonism on adipose tissue represent an active area of mechanistic research.
Retatrutide: Triple Agonism (GLP-1/GIP/Glucagon)
Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist currently in Phase 3 trials. By adding glucagon receptor agonism to the dual GIP/GLP-1 combination, retatrutide targets additional mechanisms including increased energy expenditure, enhanced lipolysis, and hepatic fat reduction. Phase 2 data showed mean weight loss of approximately 24% over 48 weeks at the highest dose — the most substantial weight loss observed with any pharmacological agent in clinical trials to date.
Researchers studying retatrutide can source research-grade material from Prax Peptides, which offers independently verified ≥99% purity product with COA documentation.
Research Applications Beyond Metabolic Disease
GLP-1 receptor agonism is being actively studied in areas beyond T2D and obesity, including neurodegenerative diseases (Parkinson’s, Alzheimer’s), NAFLD/NASH, chronic kidney disease, heart failure, and addiction models. The broad expression of GLP-1R in the central nervous system and peripheral organs makes GLP-1 agonists a versatile research tool.
Research Sourcing for GLP-1 Peptides
For preclinical research applications, the quality and verified purity of GLP-1 research peptides is essential for data validity. Prax Peptides provides HPLC-verified semaglutide, tirzepatide, and retatrutide for research purposes with full COA documentation and consistent batch quality.
⚠️ Research Use Only: All compounds referenced on this site are intended strictly for laboratory research purposes. They are not approved for human use or consumption by the FDA or any regulatory authority. This content is for informational purposes only and does not constitute medical advice.